PAEDIATRIC
PAEDIATRIC
RESPIRATORY INFECTIONS
LOWER RESPIRATORY TRACT INFECTION
1.1 Outpatient
Pneumonia (outpatient)
Infant (≥3 months) & children
Viral infection is more common
(Influenza, RSV, human metapneumovirus (hMPV), Parainfluenza, Adenovirus)
Bacteria
(S. pneumoniae, Group A Streptococcus, S. aureus, H. influenza)
Preferred
*High dose amoxicillin (80-90mg/kg/day) PO in 2 divided doses (max. 4000mg/day) for 5-7 days
Oral weight bands:
3-5kg: 250mg q12h
6-9kg: 375mg q12h
10-14kg: 500mg q12h
15-19kg: 750mg q12h
> 20kg: 500mg q8h or 1g q12h
For influenza: If suspected, treatment to be initiated as early as possible.
Oseltamivir
<9 months old: 3mg/kg PO q12h for 5 days
9-11 months old: 3.5mg/kg PO q12h for 5 days
1-12 years old:
≤15 kg: 30mg PO q12h
>15-23kg: 45mg PO q12h
>23-40kg: 60mg PO q12h
>40 kg: 75mg PO q12h
Treatment for 5 days
Alternative
Erythromycin ethylsuccinate 30-50mg/kg/day PO in 2 divided doses (max. 2g/day)
Comments
Antibiotics are not routinely recommended since viral infection is more common. For infant & children admitted to hospital, treat as presumed bacterial unless viral origin is known.
Macrolide antibiotics should be used if either mycoplasma or chlamydia pneumonia is suspected. It may be started in school-going children where disease predominates.
Duration: minimum 5 days and until afebrile for 2-3 days in empiric therapy with absence of an identified specific etiology and specific therapy with known pneumonia due to pneumococcus, HI & Moraxella catarrhalis.
* At least 40mg/kg/dose, children who do not respond to oral Amoxicillin should be referred to the center with appropriate second line treatment.
Experts recommend using high dose amoxicillin to overcome resistance conferred by cell wall changes of the bacteria (pneumococcus).
Standard dose: Amoxicillin 45-50mg/kg/day PO in 3 divided doses for 5-7 days, to be considered only for children who cannot tolerate high doses.
1.2 Inpatient
Pneumonia (inpatient, fully immunised)
Preferred
Benzylpenicillin 150,000-200,000units/kg IV in 3-4 divided doses (max. 24million unit/day) for 5-7 days
Alternative
Second line/partially treated
Cefuroxime 100-150mg/kg/day IV in 3 divided doses (max. 6g/day)
OR
Amoxicillin/clavulanate 25mg/kg/dose IV q8h (Amoxicillin max. 1g/dose) *
Comments
Macrolide antibiotics should be used if either mycoplasma or Chlamydia pneumonia is suspected.
*Amoxicillin dosage, 5:1 formulation
Child not fully immunised/life-threatening
Preferred
Cefotaxime 150-200mg/kg/day in 3 to 4 divided doses (max. 8g/day)
OR
Ceftriaxone 75-100mg/kg/day in 2 divided doses (max. 4g/day)
MAY ADD
*Azithromycin 10mg/kg/dose (max. 500mg) IV q24h on Day 1; then 5mg/kg/dose (max. 250mg) on Day 2-5 if considering atypical organisms
Alternative
Cefuroxime 100-150mg/kg/day IV in 3 divided doses (max. 6g/day)
MAY ADD
*Azithromycin 10mg/kg/dose (max. 500mg/day) IV q24h on Day 1; then 5mg/kg/dose (max. 250mg/day) on Day 2-5 if considering atypical organisms
Comments
Duration: 5-7 days. Consider longer treatment and assess for complications e.g empyema, if patient not fully recovered.
For the management of empyema, refer to Empyema thoracis section.
*The role of antimicrobials in treating both M. pneumoniae and C. pneumoniae is unknown because most children resolve infection without macrolides, treatment may be appropriate to hasten recovery in children who are more seriously ill or have a persistent cough.
Macrolide resistance is now very common in M. pneumoniae in Asia and routine use should be avoided.
Empyema thoracis (lung empyema)
Staphylococcus aureus
Streptococcus pneumoniae
Empirical treatment needs to cover organisms mentioned above.
Other bacteria implicated:
Streptococcus pyogenes,
Haemophilus influenzae & other Gram-negative organisms in immunocompromised individuals
If patient is not responding to treatment, need to rule out TB
Preferred
Cefuroxime 100-200mg/kg/day IV in 3 divided doses (max. 4.5g/day)
OR
Cefotaxime 200-300/kg IV in 4 divided doses (max.8g/day)
PLUS
Cloxacillin 200-300mg/kg/day IV in 4-6 divided doses (max.12g/day)
Duration: 4-6 weeks
Alternative
Staphylococcus aureus (methicillin-sensitive)
Cloxacillin 200-300mg/kg/day IV in 4-6 divided doses (max.12g/day) for 4-6 weeks
Streptococcus pneumoniae (penicillin-sensitive)
Benzylpenicillin 200,000-300,000 units/kg/day IV in 4-6 divided doses (max. 24 million unit/day)
Streptococcus pneumoniae (penicillin- resistant, use result of C&S)
Cefotaxime 200-300mg/kg/day IV in 4 divided doses (max. 8g/day)
OR
Ceftriaxone 100mg/kg/day IV in 1-2 divided doses (max. 4g/day)
Comments
Based on C&S of pleural fluid/tissue or blood culture.
All children with empyema need to receive high dose antibiotic therapy via intravenous route to ensure pleural penetration.
Pneumatocele on chest x-ray indicate S. aureus BUT they can also be seen in pneumococcal disease.
There is NO CONSENSUS on how long antibiotic needs to be given. Most recommend 3-6 weeks of total antibiotics depending on severity.
For moderate to severe or Stage 1-2 parapneumonic effusion, to consider pleural drainage and intrapleural fibrinolytic agent on top of antimicrobial therapy.
Stage 2 failed medical therapy and stage 3 empyema thoracis need surgical intervention. (Refer Empyema Thoracic in Children: Consensus Guideline from Malaysia Pediatric Empyema Thoracic Working Group 2020 Edition)
References:
M. Harris, J. Clark, N. Coote et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax, vol. 66, no. 2, pp. ii1– ii23.
Bradley JS, Byington CL, Shah SS et al. The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America Clinical Infectious Diseases 2011;53(7): e25–e76
Daniele Dona et al. Treatment of Community-Acquired Pneumonia: Are All Countries Treating Children in the Same Way? A Literature Review. International Journal of Pediatrics Volume 2017.
The Sanford guide to antimicrobial therapy 52nd Edition 2022
American Academy of Paediatrics. Committee on Infectious Diseases. Red Book: Report of the committee on Infectious Diseases (2021-2024 32nd Edition).
Canadian Pediatric Society Uncomplicated pneumonia in healthy Canadian children and youth: Practice points for management. (Last updated, July 2023).
The WHO AwaRe (Acess, Watch, Researve) antibiotics book, WHO 2022.
British National Formulary for Children 2022-2023
Paediatric Empyema Thoracis recommendations for management: Position Statement from the Thoracic Society of Australia and New Zealand 2010.
Manual Of Childhood Infections-Blue Book 4th edition; Oxford University Press 2016.
Guideline For The Management Of Community Acquired Pneumonia In Children; Update 2011.Thorax October 2011: vol 66 (supplement 2).
Malaysian Thoracic Society Empyema Thoracic in Children Education Program, First Edition, 2020
Clinical Practice Guideline, The Royal Children’s Hospital Melbourne, Parapneumonia effusion update 2022
Paediatric Empyema Thoracis recommendations for management: Position Statement from the MOH. Approach and management of empyema thoracis in children: a consensus guideline from the paediatric empyema working group 2
Micromedex Pediatric Reference version 5.5.0(485)